KR20170063722A - 선천적 면역 반응의 종양 유도된 면역억제를 차단하기 위한 방법으로서의 아넥신 v의 사용 - Google Patents

선천적 면역 반응의 종양 유도된 면역억제를 차단하기 위한 방법으로서의 아넥신 v의 사용 Download PDF

Info

Publication number
KR20170063722A
KR20170063722A KR1020177010186A KR20177010186A KR20170063722A KR 20170063722 A KR20170063722 A KR 20170063722A KR 1020177010186 A KR1020177010186 A KR 1020177010186A KR 20177010186 A KR20177010186 A KR 20177010186A KR 20170063722 A KR20170063722 A KR 20170063722A
Authority
KR
South Korea
Prior art keywords
annexin
cancer
tumor
cells
agents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020177010186A
Other languages
English (en)
Korean (ko)
Inventor
프란시스 제라드 브란켄버그
Original Assignee
더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티
더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티, 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 filed Critical 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티
Publication of KR20170063722A publication Critical patent/KR20170063722A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
KR1020177010186A 2014-10-03 2015-10-02 선천적 면역 반응의 종양 유도된 면역억제를 차단하기 위한 방법으로서의 아넥신 v의 사용 Withdrawn KR20170063722A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462059669P 2014-10-03 2014-10-03
US62/059,669 2014-10-03
PCT/US2015/053828 WO2016054574A1 (en) 2014-10-03 2015-10-02 Use of annexin v as a method to block tumor induced immunosuppression of the innate immune response

Publications (1)

Publication Number Publication Date
KR20170063722A true KR20170063722A (ko) 2017-06-08

Family

ID=55631651

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020177010186A Withdrawn KR20170063722A (ko) 2014-10-03 2015-10-02 선천적 면역 반응의 종양 유도된 면역억제를 차단하기 위한 방법으로서의 아넥신 v의 사용

Country Status (7)

Country Link
US (2) US11253568B2 (cg-RX-API-DMAC7.html)
EP (1) EP3200811A4 (cg-RX-API-DMAC7.html)
JP (1) JP2017530130A (cg-RX-API-DMAC7.html)
KR (1) KR20170063722A (cg-RX-API-DMAC7.html)
AU (1) AU2015327887A1 (cg-RX-API-DMAC7.html)
CA (1) CA2962255A1 (cg-RX-API-DMAC7.html)
WO (1) WO2016054574A1 (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102481271A (zh) 2009-05-11 2012-05-30 博格生物系统有限责任公司 利用表观代谢转变剂、多维细胞内分子或环境影响剂治疗代谢障碍的方法
CA2832324C (en) 2011-04-04 2022-03-15 Berg Llc Methods of treating central nervous system tumors
NZ713868A (en) 2013-04-08 2021-12-24 Berg Llc Treatment of cancer using coenzyme q10 combination therapies
KR102370843B1 (ko) 2013-09-04 2022-03-04 버그 엘엘씨 코엔자임 q10의 연속주입에 의한 암치료 방법
JP2017530130A (ja) * 2014-10-03 2017-10-12 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 腫瘍が誘発する自然免疫応答の免疫抑制を阻害する方法としてのアネキシンｖの使用
WO2017087576A1 (en) 2015-11-16 2017-05-26 Berg Llc Methods of treatment of temozolomide-resistant glioma using coenzyme q10
US20180021270A1 (en) * 2016-07-21 2018-01-25 Berg Llc Methods for the treatment of cancer using coenzyme q10 in combination with immune checkpoint modulators
WO2019010181A1 (en) * 2017-07-05 2019-01-10 The Board Of Trustees Of The Leland Stanford Junior University USE OF ANNEXIN V TO REDUCE THE PROPAGATION OF INTRACELLULAR PATHOGENIC AGENTS
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
EP4178586A4 (en) * 2020-07-09 2024-10-09 Shanghai Institute of Materia Medica, Chinese Academy of Sciences Compositions and methods for inhibiting ythdf1
WO2022212352A1 (en) * 2021-03-29 2022-10-06 The Board Of Trustees Of The Leland Stanford Junior University Reversal of ctl exhaustion with annexin v
WO2023130112A1 (en) * 2022-01-03 2023-07-06 The Board Of Trustees Of The Leland Stanford Junior University Blocking and reversing extracellular vesicle driven transcriptomic transformation with annexin v treatment

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7262167B2 (en) * 1995-11-06 2007-08-28 Exibona Ltd. Drug, in particular for modulating the immunological response for the control of viruses, tumors, bacteria and parasites
US6818213B1 (en) * 1998-07-13 2004-11-16 Board Of Regents, The University Of Texas System Cancer treatment compositions comprising therapeutic conjugates that bind to aminophospholipids
US7635680B2 (en) * 2001-02-21 2009-12-22 Alavita Pharmaceuticals, Inc. Attenuation of reperfusion injury
CA2443314C (en) * 2001-04-03 2006-03-21 The Board Of Trustees Of The Leland Stanford Junior University Method of imaging cell death in vivo
DE10145254A1 (de) 2001-09-13 2003-04-10 November Ag Molekulare Medizin Verwendung eines Proteins zur Herstellung eines Medikaments zur Stimulierung einer inflammatorischen zellulären Immunantwort
DE10302422A1 (de) * 2003-01-21 2004-07-29 Responsif Gmbh Medikament und Verwendung zur Tumortherapie
US8071545B2 (en) * 2005-03-15 2011-12-06 Lewis S. Coleman, Md, Inc. Therapies and compositions for controlling the stress mechanism and for stabilizing hemostasis in an organism
GB0911042D0 (en) * 2009-06-25 2009-08-12 Istituto Superiore Di Sanito Treatment of tumorigenic cells in solid tumours
JP2017530130A (ja) * 2014-10-03 2017-10-12 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 腫瘍が誘発する自然免疫応答の免疫抑制を阻害する方法としてのアネキシンｖの使用

Also Published As

Publication number Publication date
WO2016054574A1 (en) 2016-04-07
US20220160829A1 (en) 2022-05-26
EP3200811A4 (en) 2018-05-02
JP2017530130A (ja) 2017-10-12
US11253568B2 (en) 2022-02-22
US20170202914A1 (en) 2017-07-20
CA2962255A1 (en) 2016-04-07
EP3200811A1 (en) 2017-08-09
AU2015327887A1 (en) 2017-04-13
US12508296B2 (en) 2025-12-30

Similar Documents

Publication Publication Date Title
US12508296B2 (en) Use of annexin V as a method to block tumor induced immunosuppression of the innate immune response
US12496345B2 (en) Method of treating cancer
US20210338701A1 (en) Dna hypomethylating agents for cancer therapy
TW202115128A (zh) FLT3L-Fc融合蛋白及其使用方法
BR112020004389A2 (pt) composição, e, método para tratar ou prevenir uma doença ou distúrbio em um indivíduo em necessidade do mesmo.
CN105828834A (zh) 检查点抑制剂和治疗剂的组合以治疗癌症
US20230404986A1 (en) Combination therapy using a chemokine receptor 2 (ccr2) antagonist and a pd-1 and/or pd-l1 inhibitor
JP2025081512A (ja) 血液がんおよび固形がんの治療のためのキメラ抗原受容体改変ｔ細胞（ｃａｒ－ｔ）
JP7061134B2 (ja) 薬剤負荷ナノ粒子が表面に結合したｃａｒ ｔ細胞の養子移入およびその使用
CA3196651A1 (en) Nanoparticle complex with defined sizes
CN110831629B (zh) 用于治疗癌症的包括abx196的组合
US20250049884A1 (en) Blocking and reversing extracellular vesicle driven transcriptomic transformation with annexin v treatment
CN119546336A (zh) 用于治疗癌症的同种异体低免疫仿生纳米囊泡
ES3008937T3 (en) Beta-alethine in combination with immune modulators and uses thereof
JP7407452B2 (ja) がんの治療及び／又は予防のための医薬
US20230065416A1 (en) Clathrin-chimetic antibody receptor constructs for immune cell activation therapy in vivo
WO2025260166A1 (en) Combination therapies and methods and uses thereof for treating cancer
US20220047701A1 (en) Combination of her2/neu antibody with heme for treating cancer
HK40121706A (zh) Car-t细胞的原位募集、重编程与释放
TW202444339A (zh) 用於改善療法不良反應之組合物及方法
JP2020533406A (ja) 癌を治療するための治療用の組み合わせおよび方法
KR20200014769A (ko) 항체 가변 도메인 및 항체 구조물

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20170414

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination